Cargando…
Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response
BACKGROUND: Tuberculosis (TB) remains a global health problem, with vaccination likely to be a necessary part of a successful control strategy. Results of the first Phase 2b efficacy trial of a candidate vaccine, MVA85A, evaluated in BCG-vaccinated infants were published last year. Although no impro...
Autores principales: | Matsumiya, Magali, Harris, Stephanie A, Satti, Iman, Stockdale, Lisa, Tanner, Rachel, O’Shea, Matthew K, Tameris, Michelle, Mahomed, Hassan, Hatherill, Mark, Scriba, Thomas J, Hanekom, Willem A, McShane, Helen, Fletcher, Helen A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061512/ https://www.ncbi.nlm.nih.gov/pubmed/24912498 http://dx.doi.org/10.1186/1471-2334-14-314 |
Ejemplares similares
-
Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
por: Harris, Stephanie A., et al.
Publicado: (2014) -
The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses
por: Tameris, Michele, et al.
Publicado: (2014) -
Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
por: McShane, Helen, et al.
Publicado: (2016) -
Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A
por: Tanner, Rachel, et al.
Publicado: (2014) -
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
por: Tameris, Michele D, et al.
Publicado: (2013)